Biochemical and transcriptomic evaluation of a 3D lung organoid platform for pre-clinical testing of active substances targeting senescence

Michelle Brand,Felix Ritzmann,Kathrin Kattler,Deivydas Milasius,Yiwen Yao,Christian Herr,Susanne H. Kirsch,Rolf Müller,Daniela Yildiz,Robert Bals,Christoph Beisswenger
DOI: https://doi.org/10.1186/s12931-023-02636-7
IF: 5.8
2024-01-04
Respiratory Research
Abstract:Chronic lung diseases such as chronic obstructive pulmonary disease and cystic fibrosis are incurable. Epithelial senescence, a state of dysfunctional cell cycle arrest, contributes to the progression of such diseases. Therefore, lung epithelial cells are a valuable target for therapeutic intervention. Here, we present a 3D airway lung organoid platform for the preclinical testing of active substances with regard to senescence, toxicity, and inflammation under standardized conditions in a 96 well format. Senescence was induced with doxorubicin and measured by activity of senescence associated galactosidase. Pharmaceutical compounds such as quercetin antagonized doxorubicin-induced senescence without compromising organoid integrity. Using single cell sequencing, we identified a subset of cells expressing senescence markers which was decreased by quercetin. Doxorubicin induced the expression of detoxification factors specifically in goblet cells independent of quercetin. In conclusion, our platform enables for the analysis of senescence-related processes and will allow the pre-selection of a wide range of compounds (e.g. natural products) in preclinical studies, thus reducing the need for animal testing.
respiratory system
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the processes related to epithelial cell senescence in chronic lung diseases. Specifically, the authors developed a 3D airway - lung organoid platform to test active substances against epithelial cell senescence, toxicity and inflammation under standard conditions. The main purpose of this platform is to reduce the need for animal experiments and provide a more effective method to screen compounds that may treat chronic lung diseases, such as natural products, novel natural products from microbial sources, anti - inflammatory drugs or approved plant extracts. The core issues of the paper are: 1. **Verify the effectiveness of the platform**: Through a series of independent experiments, using organoids from different donors, verify whether the proposed anti - aging drugs (such as quercetin and dasatinib) can effectively combat doxorubicin - induced cell senescence. 2. **Evaluate the cytotoxicity of drugs**: Record the integrity of tracheal spheroids, and determine the metabolic activity as well as the release of lactate dehydrogenase (LDH) and cytokines to evaluate whether the substances used are cytotoxic. 3. **Analyze the effect of drugs on the release of inflammatory mediators**: The study found that quercetin and dasatinib can selectively inhibit the release of epithelial mediators, indicating that this platform can easily handle standardized drug testing and can measure different endpoints in one test. Through these studies, the authors hope to find a method that can find new treatment options for chronic lung diseases without conducting animal experiments.